As reported previously, we confirm autoradiography and immunohistochemistry data 2, 24 showing that human pancreatic acini do express GLP1R, although in much lower density than the insulin-producing cells
For type 2 diabetes management , NICE guideline NG28 recommends considering GLP-1 receptor agonists when: Triple therapy with metformin and two other oral medications is ineffective, not tolerated or contraindicated The patient has a body mass index (BMI) of 35 kg/m or higher (with lower thresholds for people from certain ethnic backgrounds), or lower BMI with specific clinical circumstances where weight loss would benefit other obesity-related comorbidities Insulin would have significant occupational implications GLP-1 therapy should only be continued beyond six months if there has been a beneficial metabolic response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0 percentage point) and weight loss of at least 3% of initial body weight
Research Sources: New England Journal of Medicine: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. May 11, 2025
If not, you may be advised on alternative options
53 As the dimers enter the nucleus they are further regulated by tissue-specific co-trans-activation factors, and then, next to estrogen response elements (ERE) to stimulate gene expression
